The role of vascular growth factors in hyperoxia-induced injury to the developing lung.
Normal pulmonary vascular development is the result of a complex interplay of growth factors, including vascular endothelial growth factor (VEGF) and the angiopoietins. Injury to the developing lung, whether due to hyperoxia or mechanical ventilation, results in disordered vascular development, ranging from an apparent arrest of microvascular development in milder injury to extensive microvascular derangement in more severe injury. Alterations in vascular growth factors may participate in these injuries. During injury to the developing animal lung, VEGF abundance is markedly decreased. In models of post-injury recovery, up-regulation of VEGF accompanies the re-establishment of normal vasculature. Alterations in lung VEGF levels in human premature infants are less clear cut. However, among humans premature newborns who later go on to develop bronchopulmonary dysplasia (BPD), VEGF production is decreased in comparison to those newborns who recover. Other angiogenic factors, such as the CXC ELR+ chemokines, are also altered in injury to the developing lung, but their specific roles in vascular injury are less clear. Strategies that enhance microvascular integrity, whether through attenuating alterations in vascular growth factors or by other means, also improve the outcome of lung injury. Such therapies may eventually offer hope in human BPD.
D'Angio
Carl T
CT
Strong Children's Research Center, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester NY, USA. carl_dangio@umc.rochester.edu
Maniscalco
William M
WM
D043925:Angiogenesis Inducing Agents / Q000502:physiology*; D000818:Animals; D016228:Endothelial Growth Factors / Q000502:physiology*; D006801:Humans; D018496:Hyperoxia / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology; D008168:Lung / Q000098:blood supply / Q000254:growth & development* / Q000473:pathology*; D008222:Lymphokines / Q000502:physiology*; D012259:Ribonuclease, Pancreatic / Q000502:physiology*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D043925:Angiogenesis Inducing Agents; D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; C046366:angiogenin; D012259:Ribonuclease, Pancreatic